Literature DB >> 2506803

Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin.

R G Hindes1, S H Willey, G M Eliopoulos, L B Rice, C T Eliopoulos, B E Murray, R C Moellering.   

Abstract

Several antimicrobial regimens were evaluated in the treatment of experimental enterococcal endocarditis due to a beta-lactamase-producing, highly gentamicin-resistant strain of Enterococcus faecalis. Ampicillin alone cleared bacteremia in the majority of rats and reduced titers of bacteria within vegetations (6.84 versus 8.80 log10 CFU/g in controls) but did not sterilize valves. Ampicillin-sulbactam combinations, vancomycin, daptomycin, and imipenem each reduced residual bacterial titers within vegetations to 4.01 log10 CFU/g or less; in 26 to 43% of animals receiving 5 days of therapy, titers of bacteria were reduced to undetectable levels. In a separate experiment, rats received ampicillin-sulbactam, daptomycin, or vancomycin for 10 days and were then observed for 10 days after termination of therapy for evidence of relapse. In surviving rats, valves remained sterile in four of five rats treated with ampicillin-sulbactam, in five of seven treated with daptomycin, but in only one of eight receiving vancomycin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506803      PMCID: PMC176055          DOI: 10.1128/AAC.33.7.1019

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; S Willey; E Reiszner; P G Spitzer; G Caputo; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

2.  Comparison of two beta-lactamase-producing strains of Streptococcus faecalis.

Authors:  B E Murray; D A Church; A Wanger; K Zscheck; M E Levison; M J Ingerman; E Abrutyn; B Mederski-Samoraj
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

3.  In vitro studies of plasmid-mediated penicillinase from Streptococcus faecalis suggest a staphylococcal origin.

Authors:  B E Murray; B Mederski-Samoraj; S K Foster; J L Brunton; P Harford
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

4.  Statistics in practice. Comparing the means of several groups.

Authors:  K Godfrey
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

5.  Studies on antibiotic synergism against enterococci. I. Bacteriologic studies.

Authors:  R C Moellering; C Wennersten; A N Weinberg
Journal:  J Lab Clin Med       Date:  1971-05

6.  Imipenem therapy of experimental Staphylococcus aureus and Streptococcus faecalis endocarditis.

Authors:  W M Scheld; J M Keeley
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

7.  Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci.

Authors:  R Auckenthaler; W R Wilson; A J Wright; J A Washington; D T Durack; J E Geraci
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

8.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

9.  Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis.

Authors:  B E Murray; B Mederski-Samaroj
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

10.  Rat model of experimental endocarditis.

Authors:  J Santoro; M E Levison
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

View more
  20 in total

Review 1.  Beta-lactamase-producing enterococci.

Authors:  B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 2.  Screening and treatment of infections caused by resistant enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

3.  Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens.

Authors:  T L Hodges; S Zighelboim-Daum; G M Eliopoulos; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 4.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 5.  Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci.

Authors:  Jose M Munita; Barbara E Murray; Cesar A Arias
Journal:  Int J Antimicrob Agents       Date:  2014-09-02       Impact factor: 5.283

Review 6.  Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s.

Authors:  R C George; A H Uttley
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

Review 7.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

8.  Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium.

Authors:  T Schülin; C Thauvin-Eliopoulos; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

9.  Antimicrobial susceptibility and molecular epidemiology of beta-lactamase-producing, aminoglycoside-resistant isolates of Enterococcus faecalis.

Authors:  S M Markowitz; V D Wells; D S Williams; C G Stuart; P E Coudron; E S Wong
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

10.  Comparison of ampicillin-sulbactam with vancomycin for treatment of experimental endocarditis due to a beta-lactamase-producing, highly gentamicin-resistant isolate of Enterococcus faecalis.

Authors:  S R Lavoie; E S Wong; P E Coudron; D S Williams; S M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.